Squarepoint
XENE icon

Squarepoint’s Xenon Pharmaceuticals XENE Stock Holding History

Squarepoint’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,554
Closed -$257K – 5532
2024
Q4 		$257K Sell
6,554
-950
-13% -$39.3K ﹤0.01% 4273
2024
Q3 		$295K Buy
+7,504
New +$303K ﹤0.01% 3458
2024
Q1 		– Sell
-8,253
Closed -$380K – 4687
2023
Q4 		$380K Buy
+8,253
New +$292K ﹤0.01% 3203
2022
Q4 		– Sell
-10,605
Closed -$383K – 3653
2022
Q3 		$383K Buy
10,605
+3,555
+50% +$128K ﹤0.01% 2339
2022
Q2 		$214K Buy
+7,050
New +$213K ﹤0.01% 2441
2022
Q1 		– Sell
-11,014
Closed -$344K – 3615
2021
Q4 		$344K Buy
+11,014
New +$329K ﹤0.01% 2376
2020
Q3 		– Sell
-24,321
Closed -$305K – 2886
2020
Q2 		$305K Buy
24,321
+4,281
+21% +$54.5K ﹤0.01% 1596
2020
Q1 		$227K Sell
20,040
-12,037
-38% -$171K 0.01% 1425
2019
Q4 		$421K Sell
32,077
-55,023
-63% -$579K ﹤0.01% 1865
2019
Q3 		$785K Sell
87,100
-5,890
-6% -$55.7K 0.01% 1384
2019
Q2 		$917K Buy
92,990
+60,863
+189% +$582K 0.01% 1312
2019
Q1 		$326K Buy
+32,127
New +$272K ﹤0.01% 1730

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Squarepoint's XENE Position: Q1 2025 in Review

Squarepoint sold out of Xenon Pharmaceuticals (XENE) in Q1 2025, closing a stake of 6,554 shares — an estimated $257K sold.

Squarepoint first reported a position in XENE in Q1 2019 and held it in 12 quarters. The position peaked at $917K in Q2 2019. 206 funds tracked by Wall St. Rank hold XENE as of Q1 2025.

  • Squarepoint reported no remaining Xenon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Squarepoint sold 6,554 Xenon Pharmaceuticals shares in Q1 2025, an estimated $257K.
  • Squarepoint first reported a position in Xenon Pharmaceuticals in Q1 2019 and held it in 12 quarters.
  • Squarepoint's Xenon Pharmaceuticals position peaked at $917K in Q2 2019.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2025.

Based on Squarepoint's 13F filing for Q1 2025, filed 15 May 2025.